Health and Healthcare

Sanofi : SNY

All Sanofi Articles

195 Articles

Jon C. Ogg | Nov 4, 2015 at 1:35 PM EST

Why RBC Is Now So Negative Against MannKind

RBC Capital Markets downgraded MannKind on Wednesday to Underperform from a Market Perform, with a price target of a mere…

Jon C. Ogg | Aug 14, 2015 at 5:19 PM EDT

Key Changes in Warren Buffett and Berkshire Hathaway Stock Holdings

courtesy of WhiteHouse.govWarren Buffett and Berkshire Hathaway Inc. (NYSE: BRK-A) have released the official equity holdings of Berkshire Hathaway as…

Chris Lange | Jul 27, 2015 at 11:53 AM EDT

Have Analysts Fully Priced in Praluent to Regeneron?

ThinkstockRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA)…

Paul Ausick | Jun 26, 2015 at 11:10 AM EDT

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

When the American Society of Clinical Oncology (ASCO) decided to create a rating scale for cancer drugs, it certainly must…

Jon C. Ogg | Jun 7, 2015 at 9:40 AM EDT

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more…

Jon C. Ogg | May 20, 2015 at 1:45 PM EDT

Has MannKind Stock Finally Bottomed Out?

After looking at the recent recovery, and after looking over the more recent news that has come out after earnings,…

Chris Lange | May 8, 2015 at 11:00 AM EDT

What to Make of MannKind Earnings

Biotech company MannKind reported its first-quarter financial results after the markets closed Thursday.

Jon C. Ogg | Feb 19, 2015 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: Coach, Garmin, Intelsat, Potbelly, SolarCity, Valero and More

Thursday's top analyst upgrades, downgrades and initiations from 24/7 Wall St. include Coach, Garmin, Intelsat, Potbelly, SolarCity and Valero Energy.

Jon C. Ogg | Feb 17, 2015 at 5:32 PM EST

Meet the 2015 Warren Buffett and Berkshire Hathaway Stocks

courtesy of WhiteHouse.govBerkshire Hathaway Inc. (NYSE: BRK-A) has made its quarterly filing with the Securities & Exchange Commission for its holdings…

Jon C. Ogg | Dec 1, 2014 at 2:10 PM EST

5 Critical Biotech Drug Dates and Events for December

At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.

Paul Ausick | Nov 18, 2014 at 9:10 AM EST

Companies Spending the Most on R&D

For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.

Jon C. Ogg | Nov 14, 2014 at 4:58 PM EST

Significant Changes in Buffett and Berkshire Hathaway Holdings

courtesy of WhiteHouse.govBerkshire Hathaway Inc. (NYSE: BRK-A) has released its public equity holdings as of September 30, 2014. Warren Buffett’s…

Jon C. Ogg | Oct 29, 2014 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Alibaba, Amgen, Cliffs, Michael Kors, Sanofi, Yahoo! and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, October 29, 2014.

Jon C. Ogg | Aug 14, 2014 at 5:17 PM EDT

Major Portfolio Changes for Warren Buffett and Berkshire Hathaway

courtesy of WhiteHouse.govBerkshire Hathaway Inc. (NYSE: BRK-A) released its public equity holdings as of June 30, 2014. Warren Buffett’s different…

Jon C. Ogg | Aug 13, 2014 at 9:53 AM EDT

What the Market Is Telling MannKind (Updated)

Jon OggMannKind Corp. (NASDAQ: MNKD) was supposed to be a huge winner on this week’s news that Sanofi (NYSE: SNY)…

1 … 3 4 5 6 7 … 13

Sanofi : SNY

All Sanofi Articles

Why RBC Is Now So Negative Against MannKind

Key Changes in Warren Buffett and Berkshire Hathaway Stock Holdings

Have Analysts Fully Priced in Praluent to Regeneron?

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

Has MannKind Stock Finally Bottomed Out?

What to Make of MannKind Earnings

Top Analyst Upgrades and Downgrades: Coach, Garmin, Intelsat, Potbelly, SolarCity, Valero and More

Meet the 2015 Warren Buffett and Berkshire Hathaway Stocks

5 Critical Biotech Drug Dates and Events for December

Companies Spending the Most on R&D

Significant Changes in Buffett and Berkshire Hathaway Holdings

Top Analyst Upgrades and Downgrades: Alibaba, Amgen, Cliffs, Michael Kors, Sanofi, Yahoo! and More

Major Portfolio Changes for Warren Buffett and Berkshire Hathaway

What the Market Is Telling MannKind (Updated)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Sanofi : SNY

All Sanofi Articles

Why RBC Is Now So Negative Against MannKind

Key Changes in Warren Buffett and Berkshire Hathaway Stock Holdings

Have Analysts Fully Priced in Praluent to Regeneron?

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

Has MannKind Stock Finally Bottomed Out?

What to Make of MannKind Earnings

Top Analyst Upgrades and Downgrades: Coach, Garmin, Intelsat, Potbelly, SolarCity, Valero and More

Meet the 2015 Warren Buffett and Berkshire Hathaway Stocks

5 Critical Biotech Drug Dates and Events for December

Companies Spending the Most on R&D

Significant Changes in Buffett and Berkshire Hathaway Holdings

Top Analyst Upgrades and Downgrades: Alibaba, Amgen, Cliffs, Michael Kors, Sanofi, Yahoo! and More

Major Portfolio Changes for Warren Buffett and Berkshire Hathaway

What the Market Is Telling MannKind (Updated)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s